May 12, 2020 / 10:42 AM / in 16 days

BRIEF-Gamida Cell Says Phase 3 Study Of Omidubicel Met Primary Endpoint Of Time To Neutrophil Engraftment

May 12 (Reuters) - Gamida Cell Ltd:

* GAMIDA CELL ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 3 CLINICAL STUDY OF OMIDUBICEL IN PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES

* GAMIDA CELL - PHASE 3 CLINICAL STUDY OF OMIDUBICEL MET PRIMARY ENDPOINT OF TIME TO NEUTROPHIL ENGRAFTMENT

* COMPANY ANTICIPATES INITIATING BLA SUBMISSION IN Q4 OF 2020

* EXPECTS TO REPORT FULL EFFICACY AND SAFETY RESULTS AT MEDICAL CONFERENCE LATER THIS YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below